ASTC

SEC Filing Summary: SPACEHAB, Incorporated (Form 10-K)

Business Context and Reporting Period

Company: SPACEHAB, Incorporated (Note: Request metadata referenced "ASTROTECH Corp," but the filing is for SPACEHAB, which owns the Astrotech subsidiary).

Reporting Period: Fiscal year ended June 30, 2008.

Overview: SPACEHAB provides space flight hardware, payload processing services, and engineering support. The company operates through five segments: Astrotech Space Operations (ASO), Astrotech Engineering Services (AES), SPACEHAB Orbital Transportation Services (SOTS), BioSpace Technologies, and SPACETECH. The company is a smaller reporting company and faces significant liquidity challenges and NASDAQ delisting risks due to share price violations.

Key Financial Metrics

Note: The 2008 Net Loss includes a non-cash debt conversion expense of $30.2 million.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped 52% to $25.5 million, primarily due to the completion of the final contracted Space Shuttle module mission (STS-118) in August 2007, eliminating revenue from the Flight Services segment. Additionally, the Engineering Services segment lost its primary NASA PI&C contract in June 2008.
• Debt Restructuring: Long-term debt decreased by $42.6 million. The company exchanged approximately $53.5 million of convertible notes for common stock and preferred stock in October 2007, resulting in the $30.2 million non-cash expense. Remaining debt consists of a $4.0 million term loan and $6.9 million in senior convertible notes.
• Asset Impairments: Unlike 2007, which saw a $12.5 million impairment charge on flight assets, 2008 had no major flight asset impairments, though inventory was written down by $0.2 million.
• Stock Performance: The company's stock price fell significantly, trading as low as $0.37 in Q4 2008, triggering a NASDAQ deficiency notice.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity Risk: The company reported a net loss of $36.0 million and negative operating cash flow of $8.6 million. While working capital improved to $1.0 million, the company relies on a $2.0 million revolving credit facility (expiring Feb 2009) and a $4.0 million term loan. Management states it has sufficient liquidity for the next fiscal year but faces uncertainty in raising capital for new initiatives.
• Contract Termination: ARES Corporation terminated the company's Cost Plus Award Fee Subcontract (PI&C) for convenience in May 2008. The company is disputing $1.4 million in receivables related to this termination.
• Backlog: As of June 30, 2008, the firm backlog was approximately $30.2 million, with 51% derived from U.S. Government contracts. The majority of the backlog is concentrated in the Astrotech Space Operations segment.
• New Business Initiatives: The company is pivoting toward commercializing space technologies (BioSpace for vaccines, SPACETECH for mass spectrometers and hazardous cargo containers). However, these segments generated no revenue in 2008 and require significant capital investment.
• NASDAQ Delisting: The company received a notice of non-compliance with NASDAQ listing rules due to a bid price below $1.00. Failure to regain compliance by October 6, 2008, could result in delisting.
• Unusual Items: The $30.2 million debt conversion expense is a significant non-cash item distorting the net loss. Excluding this, the company's operational performance was less severe than the bottom line suggests.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the new bank financing facility covenants (minimum tangible net worth, cash flow coverage) to ensure the $2.0 million revolving credit line remains available.
• NASDAQ Compliance: Monitor the company's ability to regain a $1.00 bid price by the October 6, 2008 deadline to avoid delisting.
• Contract Dispute Resolution: Track the status of the $1.4 million receivable dispute with ARES Corporation regarding the terminated PI&C subcontract.
• Capital Requirements: Assess the company's ability to fund the development of BioSpace and SPACETECH products without further dilutive equity offerings, given the current cash burn rate.
• Backlog Realization: Confirm that the $30.2 million backlog, heavily reliant on government contracts, is not subject to "termination for convenience" clauses that could erase future revenue.